Loading
institutionsInstitution
LMU Klinikum München
LMU Klinikum is Munich's university cancer centre, with strengths in PSMA theranostics and haematology.
Overview
LMU Klinikum München is the university hospital of Ludwig-Maximilians-Universität and, with TUM, forms the Comprehensive Cancer Center Munich; it ranks thirty-first in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. Its nuclear medicine leadership in PSMA imaging and radioligand therapy is the reason it appears on theranostics pages, and haematology is its other declared strength, with Peter Bartenstein, Michael von Bergwelt, Martin Dreyling, Nadia Harbeck, Volker Heinemann and Claus Belka among the people OnCo lists. OnCo links it to PSMA PET, to the European Association of Nuclear Medicine and Deutsche Krebshilfe, and to its partner TUM Klinikum rechts der Isar. How theranostics scales from a few academic centres to routine care is the open question. Its theranostics and haematology programmes are listed below.
Location
Munich, DE
Type
university · Ludwig-Maximilians-Universität
Website
Newsweek 2026 oncology rank
#31
OnCo score
#91 · 41 points (29 Newsweek + 0 NCI + 12 from 6 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Ludwig-Maximilians-Universität München, including child institutions. 1,954 works · 23,788 citations · 73% open access · 12% clinical trials · 2% reviews.
Oncology works per year
4072022
4162023
3992024
4212025
3112026
Most works
- Volker Heinemann149 works
- Kai Rejeski123 works
- Michael von Bergwelt‐Baildon91 works
- Marion S. Subklewe81 works
- Sebastian Stintzing79 works
- Nadia Harbeck78 works
- Dominik Paul Modest76 works
- Sebastian Kobold73 works
- Arndt Stahler60 works
- Ludwig Fischer von Weikersthal57 works
Most cited
- Theranostics
- Haematology
Claus Belka
Director, Department of Radiation Oncology, LMU Munich
Radiation oncologyMR-guided radiotherapyRadiobiology
Claus Belka is a radiation oncologist leading MR-guided adaptive radiotherapy research in Munich.
Martin Dreyling
Professor of Medicine and Head of the Lymphoma Program, LMU University Hospital Munich; Chair, European MCL Network
Mantle cell lymphomaFirst-line therapyBTK inhibitors
Chairs the European MCL Network and led TRIANGLE, which showed ibrutinib can replace transplant in younger mantle cell lymphoma patients.
Michael von Bergwelt
Director, Department of Medicine III (Hematology and Oncology), LMU Munich
HaematologyCell therapyImmunotherapy toxicity
Michael von Bergwelt is a haematologist who leads LMU's cell therapy and immuno-oncology programme.
Nadia Harbeck
Head of the Breast Center, LMU University Hospital Munich; Chair, West German Study Group
Early breast cancerBiomarker-driven de-escalationHER2-positive disease
German breast oncologist whose ADAPT trials use biology to decide who can have less chemotherapy.
Peter Bartenstein
Director, Department of Nuclear Medicine, LMU Munich
Nuclear medicinePSMA theranosticsNeuro-imaging
Peter Bartenstein is a nuclear medicine head whose department is a leading European PSMA theranostics centre.
Volker Heinemann
Director, Comprehensive Cancer Center Munich (LMU); Professor of Medical Oncology
Colorectal cancerPancreatic cancerAnti-EGFR therapy
Gastrointestinal oncologist who led FIRE-3, a key trial of cetuximab versus bevacizumab in colorectal cancer.
Similar pages
- Treatment177Lu-PSMA-I&T
Shares Peter Bartenstein, PSMA PET.
- InstitutionComprehensive Cancer Center Freiburg (CCCF)
Shares German Cancer Consortium (DKTK), PSMA PET.
- PersonKen Herrmann
- PersonUwe Haberkorn
- TrialSHINE
Shares Martin Dreyling, TRIANGLE.
- InstitutionGerman Cancer Research Center (DKFZ)
Shares Deutsche Krebshilfe, German Cancer Consortium (DKTK), TUM Klinikum rechts der Isar / CCC München.
- TermTheranostics
Shares TUM Klinikum rechts der Isar / CCC München, European Association of Nuclear Medicine, PSMA PET.
- InstitutionSociety of Nuclear Medicine and Molecular Imaging